Trial Profile
Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Dec 2012
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Nov 2008 New trial record.